{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T09:17:15Z","timestamp":1784279835916,"version":"3.55.0"},"reference-count":37,"publisher":"Japanese Society of Toxicology","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Toxicol. Sci."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2131\/jts.51.75","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:10:40Z","timestamp":1767651040000},"page":"75-87","source":"Crossref","is-referenced-by-count":2,"title":["Predicting nucleic acid drug-induced nephrotoxicity using a 3D human renal proximal tubule spheroid model"],"prefix":"10.2131","volume":"51","author":[{"given":"Kaoru","family":"Morimura","sequence":"first","affiliation":[{"name":"Bio Business Promotion Department, Medical Division, NIKKISO Co., Ltd."},{"name":"Department of Systems Bioscience, Graduate School of Systems Life Sciences, Kyushu University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsushi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Bio Business Promotion Department, Medical Division, NIKKISO Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayata","family":"Maeda","sequence":"additional","affiliation":[{"name":"Bio Business Promotion Department, Medical Division, NIKKISO Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Nishioka","sequence":"additional","affiliation":[{"name":"Bio Business Promotion Department, Medical Division, NIKKISO Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayano","family":"Araki","sequence":"additional","affiliation":[{"name":"Bio Business Promotion Department, Medical Division, NIKKISO Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Mizumoto","sequence":"additional","affiliation":[{"name":"Department of Systems Bioscience, Graduate School of Systems Life Sciences, Kyushu University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Jimbo","sequence":"additional","affiliation":[{"name":"Bio Business Promotion Department, Medical Division, NIKKISO Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"898","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Alhamadani, F., Zhang, K., Parikh, R., Wu, H., Rasmussen, T.P., Bahal, R., Zhong, X.B. and Manautou, J.E. (2022): Adverse Drug Reactions and Toxicity of the Food and Drug Administration-Approved Antisense Oligonucleotide Drugs. Drug Metab. Dispos., <b>50<\/b>, 879-887.","DOI":"10.1124\/dmd.121.000418"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Arakawa, H., Higuchi, D., Takahashi, E., Matsushita, K., Nedachi, S., Peng, H., Kadoguchi, M., Morimura, K., Araki, A., Kondo, M., Ishiguro, N., Jimbo, Y. and Tamai, I. (2024): Three-dimensional culture of human proximal tubular epithelial cells for an <i>in vitro<\/i> evaluation of drug-induced kidney injury. J. Pharm. Sci., <b>113<\/b>, 3255-3264.","DOI":"10.1016\/j.xphs.2024.08.009"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Cardarelli, F., Digiacomo, L., Marchini, C., Amici, A., Salomone, F., Fiume, G., Rossetta, A., Gratton, E., Pozzi, D. and Caracciolo, G. (2016): The intracellular trafficking mechanism of Lipofectamine-based transfection reagents and its implication for gene delivery. Sci. Rep., <b>6<\/b>, 25879.","DOI":"10.1038\/srep25879"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Coca, S.G., Yalavarthy, R., Concato, J. and Parikh, C.R. (2008): Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. Kidney Int., <b>73<\/b>, 1008-1016.","DOI":"10.1038\/sj.ki.5002729"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Demichev, V., Messner, C.B., Vernardis, S.I., Lilley, K.S. and Ralser, M. (2020): DIA-NN: neural networks and interference correction enable deep proteome coverage in high throughput. Nat. Methods, <b>17<\/b>, 41-44.","DOI":"10.1038\/s41592-019-0638-x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Dieckmann, A., Hagedorn, P.H., Burki, Y., Br\u00fcgmann, C., Berrera, M., Ebeling, M., Singer, T. and Schuler, F. (2018): A Sensitive In Vitro Approach to Assess the Hybridization-Dependent Toxic Potential of High Affinity Gapmer Oligonucleotides. Mol. Ther. Nucleic Acids, <b>10<\/b>, 45-54.","DOI":"10.1016\/j.omtn.2017.11.004"},{"key":"7","doi-asserted-by":"crossref","unstructured":"DiMasi, J.A., Grabowski, H.G. and Hansen, R.W. (2016): Innovation in the pharmaceutical industry: new estimates of R&amp;D costs. J. Health Econ., <b>47<\/b>, 20-33.","DOI":"10.1016\/j.jhealeco.2016.01.012"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Goyenvalle, A., Jimenez-Mallebrera, C., van Roon, W., Sewing, S., Krieg, A.M., Arechavala-Gomeza, V. and Andersson, P. (2023): Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides. Nucleic Acid Ther., <b>33<\/b>, 1-16.","DOI":"10.1089\/nat.2022.0061"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Hirabayashi, Y., Maki, K., Kinoshita, K., Nakazawa, T., Obika, S., Naota, M., Watanabe, K., Suzuki, M., Arato, T., Fujisaka, A., Fueki, O., Ito, K. and Onodera, H. (2021): Considerations of the Japanese Research Working Group for the ICH S6 &amp; Related Issues Regarding Nonclinical Safety Assessments of Oligonucleotide Therapeutics: Comparison with Those of Biopharmaceuticals. Nucleic Acid Ther., <b>31<\/b>, 114-125.","DOI":"10.1089\/nat.2020.0879"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Hornberg, J.J., Laursen, M., Brenden, N., Persson, M., Thougaard, A.V., Toft, D.B. and Mow, T. (2014): Exploratory toxicology as an integrated part of drug discovery. Part I: why and how. Drug Discov. Today, <b>19<\/b>, 1131-1136.","DOI":"10.1016\/j.drudis.2013.12.008"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Hughes, R.D., Mitry, R.R., Dhawan, A., Lehec, S.C., Girlanda, R., Rela, M., Heaton, N.D. and Muiesan, P. (2006): Isolation of hepatocytes from livers from non-heart-beating donors for cell transplantation. Liver Transpl., <b>12<\/b>, 713-717.","DOI":"10.1002\/lt.20732"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Ishiguro, N., Takahashi, E., Arakawa, H., Saito, A., Kitagawa, F., Kondo, M., Morinaga, G., Takatani, M., Takahashi, R., Kudo, T., Mae, S.I., Kadoguchi, M., Higuchi, D., Nakazono, Y., Tamai, I., Osafune, K. and Jimbo, Y. (2023): Improvement of protein expression profile in three-dimensional renal proximal tubular epithelial cell spheroids selected based on OAT1 gene expression: a potential <i>in vitro<\/i> tool for evaluating human renal proximal tubular toxicity and drug disposition. Drug Metab. Dispos., <b>51<\/b>, 1177-1187.","DOI":"10.1124\/dmd.122.001171"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Jenkinson, S.E., Chung, G.W., van Loon, E., Bakar, N.S., Dalzell, A.M. and Brown, C.D. (2012): The limitations of renal epithelial cell line HK-2 as a model of drug transporter expression and function in the proximal tubule. Pflugers Arch., <b>464<\/b>, 601-611.","DOI":"10.1007\/s00424-012-1163-2"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Kawashima, Y., Nagai, H., Konno, R., Ishikawa, M., Nakajima, D., Sato, H., Nakamura, R., Furuyashiki, T. and Ohara, O. (2022): Single-Shot 10K Proteome Approach: Over 10,000 Protein Identifications by Data-Independent Acquisition-Based Single-Shot Proteomics with Ion Mobility Spectrometry. J. Proteome Res., <b>21<\/b>, 1418-1427.","DOI":"10.1021\/acs.jproteome.2c00023"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Kwiatkowska, E., Doma\u0144ski, L., Dziedziejko, V., Kajdy, A., Stefa\u0144ska, K. and Kwiatkowski, S. (2021): The mechanism of drug nephrotoxicity and the methods for preventing kidney damage. Int. J. Mol. Sci., <b>22<\/b>, 11.","DOI":"10.3390\/ijms22116109"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Lazareth, H., Poli, A., Bignon, Y., Mirmiran, A., Rabant, M., Cohen, R., Schmitt, C., Puy, H., Karras, A., Gouya, L. and Pallet, N. (2021): Renal Function Decline With Small Interfering RNA Silencing Aminolevulinic Acid Synthase 1 (ALAS1). Kidney Int. Rep., <b>6<\/b>, 1904-1911.","DOI":"10.1016\/j.ekir.2021.04.004"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Lou, R. and Shui, W. (2024): Acquisition and Analysis of DIA-Based Proteomic Data: A Comprehensive Survey in 2023. Mol. Cell. Proteomics, <b>23<\/b>, 100712.","DOI":"10.1016\/j.mcpro.2024.100712"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Masuda, T., Saito, N., Tomita, M. and Ishihama, Y. (2009): Unbiased quantitation of Escherichia coli membrane proteome using phase transfer surfactants. Mol. Cell. Proteomics, <b>8<\/b>, 2770-2777.","DOI":"10.1074\/mcp.M900240-MCP200"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Monticello, T.M., Jones, T.W., Dambach, D.M., Potter, D.M., Bolt, M.W., Liu, M., Keller, D.A., Hart, T.K. and Kadambi, V.J. (2017): Current nonclinical testing paradigm enables safe entry to First-In-Human clinical trials: the IQ consortium nonclinical to clinical translational database. Toxicol. Appl. Pharmacol., <b>334<\/b>, 100-109.","DOI":"10.1016\/j.taap.2017.09.006"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Morgan, P., Brown, D.G., Lennard, S., Anderton, M.J., Barrett, J.C., Eriksson, U., Fidock, M., Hamr\u00e9n, B., Johnson, A., March, R.E., Matcham, J., Mettetal, J., Nicholls, D.J., Platz, S., Rees, S., Snowden, M.A. and Pangalos, M.N. (2018): Impact of a five-dimensional framework on R&amp;D productivity at AstraZeneca. Nat. Rev. Drug Discov., <b>17<\/b>, 167-181.","DOI":"10.1038\/nrd.2017.244"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Nielsen, R., Christensen, E.I. and Birn, H. (2016): Megalin and cubilin in proximal tubule protein reabsorption: from experimental models to human disease. Kidney Int., <b>89<\/b>, 58-67.","DOI":"10.1016\/j.kint.2015.11.007"},{"key":"22","unstructured":"NS Pharma, VILTEPSO (Viltolarsen) injection, for intravenous"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Petreski, T., Varda, L., Gradi\u0161nik, L., Maver, U. and Bevc, S. (2023): Renal Proximal Tubular Epithelial Cells: From Harvesting to Use in Studies. Nephron, <b>147<\/b>, 650-654.","DOI":"10.1159\/000531291"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Ryan, M.J., Johnson, G., Kirk, J., Fuerstenberg, S.M., Zager, R.A. and Torok-Storb, B. (1994): HK-2: an immortalized proximal tubule epithelial cell line from normal adult human kidney. Kidney Int., <b>45<\/b>, 48-57.","DOI":"10.1038\/ki.1994.6"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Secker, P.F., Schlichenmaier, N., Beilmann, M., Deschl, U. and Dietrich, D.R. (2019): Functional transepithelial transport measurements to detect nephrotoxicity <i>in vitro<\/i> using the RPTEC\/TERT1 cell line. Arch. Toxicol., <b>93<\/b>, 1965-1978.","DOI":"10.1007\/s00204-019-02469-8"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Tang, C., Livingston, M.J., Safirstein, R. and Dong, Z. (2023): Cisplatin nephrotoxicity: new insights and therapeutic implications. Nat. Rev. Nephrol., <b>19<\/b>, 53-72.","DOI":"10.1038\/s41581-022-00631-7"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Tian, Z. and Liang, M. (2021): Renal metabolism and hypertension. Nat. Commun., <b>12<\/b>, 963.","DOI":"10.1038\/s41467-021-21301-5"},{"key":"28","doi-asserted-by":"crossref","unstructured":"van Poelgeest, E.P., Swart, R.M., Betjes, M.G., Moerland, M., Weening, J.J., Tessier, Y., Hodges, M.R., Levin, A.A. and Burggraaf, J. (2013): Acute kidney injury during therapy with an antisense oligonucleotide directed against PCSK9. Am. J. Kidney Dis., <b>62<\/b>, 796-800.","DOI":"10.1053\/j.ajkd.2013.02.359"},{"key":"29","doi-asserted-by":"crossref","unstructured":"van Poelgeest, E.P., Hodges, M.R., Moerland, M., Tessier, Y., Levin, A.A., Persson, R., Lindholm, M.W., Dumong Erichsen, K., \u00d8rum, H., Cohen, A.F. and Burggraaf, J. (2015): Antisense-mediated reduction of proprotein convertase subtilisin\/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial. Br. J. Clin. Pharmacol., <b>80<\/b>, 1350-1361.","DOI":"10.1111\/bcp.12738"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Varda, L., Petreski, T., Gradi\u0161nik, L., Maver, U. and Bevc, S. (2025): Narrative review of proximal tubular epithelial cell in-vitro co-culture models. Biofabrication, <b>17<\/b>, 1.","DOI":"10.1088\/1758-5090\/ad9407"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Wang, Z., do Carmo, J.M., da Silva, A.A., Fu, Y. and Hall, J.E. (2020): Mechanisms of Synergistic Interactions of Diabetes and Hypertension in Chronic Kidney Disease: Role of Mitochondrial Dysfunction and ER Stress. Curr. Hypertens. Rep., <b>22<\/b>, 15.","DOI":"10.1007\/s11906-020-1016-x"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Wardwell-Swanson, J., Suzuki, M., Dowell, K.G., Bieri, M., Thoma, E.C., Agarkova, I., Chiovaro, F., Strebel, S., Buschmann, N., Greve, F. and Frey, O. (2020): A Framework for Optimizing High-Content Imaging of 3D Models for Drug Discovery. SLAS Discov., <b>25<\/b>, 709-722.","DOI":"10.1177\/2472555220929291"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Wolf-Yadlin, A., Hu, A. and Noble, W.S. (2016): Technical advances in proteomics: new developments in data-independent acquisition. F1000 Res., <b>5<\/b>.","DOI":"10.12688\/f1000research.7042.1"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Wu, H., Wahane, A., Alhamadani, F., Zhang, K., Parikh, R., Lee, S., McCabe, E.M., Rasmussen, T.P., Bahal, R., Zhong, X.B. and Manautou, J.E. (2022): Nephrotoxicity of marketed antisense oligonucleotide drugs. Curr. Opin. Toxicol., <b>32<\/b>.","DOI":"10.1016\/j.cotox.2022.100373"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Xiao, X., Zhang, J., Lang, Y., Cai, L., Yang, Q., Liu, K., Ji, S., Ju, X. and Liu, F. (2023): Associations of lactate dehydrogenase with risk of renal outcomes and cardiovascular mortality in individuals with diabetic kidney disease. Diabetes Res. Clin. Pract., <b>203<\/b>, 110838.","DOI":"10.1016\/j.diabres.2023.110838"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Xu, G., Ni, Y., Cui, C., Du, J., Duan, M., Yang, Y. and Yu, C. (2025): Development and validation of a cell-based assay to determine the bioactivity of antibodies against CD39 targets. J. Pharm. Biomed. Anal., <b>265<\/b>, 117021.","DOI":"10.1016\/j.jpba.2025.117021"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Zou, C., Wang, C. and Lu, L. (2022): Advances in the study of subclinical AKI biomarkers. Front. Physiol., <b>13<\/b>, 960059.","DOI":"10.3389\/fphys.2022.960059"}],"container-title":["The Journal of Toxicological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jts\/51\/1\/51_75\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T04:12:06Z","timestamp":1768018326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jts\/51\/1\/51_75\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2131\/jts.51.75","relation":{},"ISSN":["0388-1350","1880-3989"],"issn-type":[{"value":"0388-1350","type":"print"},{"value":"1880-3989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]}}}